Exosens: Stifel raises target price

(CercleFinance.com) - Stifel reiterates its 'buy' recommendation on Exosens shares, with a target price raised from E30 to E38, to take into account better visibility on growth and higher market potential for this high-tech company.


Exosens' share price has appreciated relative to defense stocks, the broker notes, for which it does not actually incorporate the untapped market potential of the recently announced expansion into the US.

Stifel also argues that a military build-up in Europe could provide an additional business opportunity of over E700m over several years, which it does not see reflected in the share price.


Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.